-Противовирусная роль NK-клеток при инфекциях CMV и SARS-CoV-2 и подходы к использованию противовирусного потенциала NK-клеток в терапии

January 6, 2022 — December 31, 2024

Kovalenko E.I. (PI)

Laboratory of cell interactions

Grant, RSF

List of publications

  1. Ustiuzhanina MO, Vavilova JD, Boyko AA, Streltsova MA, Kust SA, Kanevskiy LM, Sapozhnikov AM, Iskhakov RN, Gubernatorova EO, Drutskaya MS, Bychinin MV, Zhukova OA, Novikova ON, Sotnikova AG, Yusubalieva GM, Baklaushev VP, Kovalenko EI (2023). Coordinated Loss and Acquisition of NK Cell Surface Markers Accompanied by Generalized Cytokine Dysregulation in COVID-19. Int J Mol Sci 24 (3), 1996
  2. Vavilova JD, Ustiuzhanina MO, Boyko AA, Streltsova MA, Kust SA, Kanevskiy LM, Iskhakov RN, Sapozhnikov AM, Gubernatorova EO, Drutskaya MS, Bychinin MV, Novikova ON, Sotnikova AG, Yusubalieva GM, Baklaushev VP, Kovalenko EI (2023). Alterations in the CD56− and CD56+ T Cell Subsets during COVID-19. Int J Mol Sci 24 (10), 9047
  3. Boyko AA, Ustiuzhanina MO, Vavilova JD, Streltsova MA, Kust SA, Siniavin AE, Astrakhantseva IV, Drutskaya MS, Kovalenko EI (2023). Phenotypic Changes in T and NK Cells Induced by Sputnik V Vaccination. Vaccines (Basel) 11 (6),
  4. Alekseeva NA, Ustyuzhanina MO, Streltsova MA, Grechikhina MV, Lutsenko GV, Kovalenko EI (2023). NK CELL EXPANSION IN VITRO IS FOLLOWED BY LOSS OF INHIBITORY KIR EXPRESSION. Medical Immunology (Russia) 25 (3), 441–446
  5. Velichinskii RA, Vavilova JD, Boyko AA, Shustova OA, Palamarchuk AI, Yusubalieva GM, Kucherova ON, Streltsova MA, Kovalenko EI (2023). UMBILICAL CORD BLOOD AS A PROMISING SOURCE OF NK CELLS FOR IMMUNOTHERAPY. Medical Immunology (Russia) 25 (5), 1259–1264
  6. (conference) Ustiuzhanina MO, Britanova OV, Kovalenko EI (2022). The impact of SARS-CoV-2 peptides on activation of NK cells. MAJ 22 (2), 261–268
  7. Alekseeva NA, Streltsova MA, Vavilova JD, Ustiuzhanina MO, Palamarchuk AI, Boyko AA, Timofeev ND, Popodko AI, Kovalenko EI (2024). Obtaining Gene-Modified HLA-E-Expressing Feeder Cells for Stimulation of Natural Killer Cells. Pharmaceutics 16 (1), 133
  8. Kust SA, Ustiuzhanina MO, Streltsova MA, Shelyakin PV, Kryukov MA, Lutsenko GV, Sudarikova AV, Merzlyak EM, Britanova OV, Sapozhnikov AM, Kovalenko EI (2024). HLA-DR Expression in Natural Killer Cells Marks Distinct Functional States, Depending on Cell Differentiation Stage. Int J Mol Sci 25 (9), 4609
  9. Streltsova MA, Palamarchuk AI, Vavilova JD, Ustiuzhanina MO, Boyko AA, Velichinskii RA, Alekseeva NA, Grechikhina MV, Shustova OA, Sapozhnikov AM, Kovalenko EI (2024). Methodological Approaches for Increasing the Retroviral Transduction Efficiency of Primary NK Cells. Curr Pharm Des 30 (37), 2947–2958
  10. Alekseeva NA, Vavilova YD, Kovalenko EI (2024). Increased proliferative response of highly differentiated CD57+NKG2C+NK cells expressing NKG2A. Medical Immunology (Russia) 26 (5), 891–896
  11. Ustiuzhanina MO, Boyko AA, Vavilova JD, Siniavin AE, Streltsova MA, Astrakhantseva IV, Drutskaya MS, Chudakov DM, Kovalenko EI (2024). The Antigen-Specific Response of NK Cells to SARS-CoV-2 Correlates With KIR2DS4 Expression. J Med Virol 96 (11), e70057